http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101705879-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101705879-B1 |
| titleOfInvention | Composition for Enhancing Sensitivity for Anti-Cancer Drug Comprising GLRX3 Inhibitors and Diagnostic Marker for Resistance of Anti-Cancer Drug |
| abstract | The present invention provides a composition for enhancing sensitivity to an anticancer agent of cancer cells or cancer tissues comprising an inhibitor of the expression of GLRX3 or an activity inhibitor. The composition of the present invention improves the susceptibility to the anticancer agent in the object, and as a result, the therapeutic effect of the anticancer agent can be enhanced, and the sensitivity of the anticancer agent can be improved, thereby reducing the dose of the anticancer agent used in combination, . The present invention provides a method for detecting an anticancer drug resistance marker GLRX3 and a kit for analyzing an anticancer drug resistance using a sample of a patient, whereby GLRX3 can be used as a predictive marker for anticancer drug resistance. The present invention provides a therapeutic composition for cancer showing an anticancer drug resistance including a GLRX3 inhibitor. |
| priorityDate | 2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 502.